This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in Massachusetts General Hospital Rumination Questionnaire (MGH-RQ)
Timeframe: Baseline, and 3 weeks, 6 weeks, 9 weeks, and 12 weeks after psilocybin administration.
Change in Resting-State Functional Connectivity
Timeframe: Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration.
Change in Self-Attribution Task performance
Timeframe: Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration.
Change in Task-Based Activity during Self-Attribution Task
Timeframe: Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration.